Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metoprolol succinate is a cardioselective beta-1 adrenergic receptor blocker used primarily for the treatment of hypertension, angina pectoris, and stable heart failure. As a small molecule antagonist, it selectively binds to beta-1 receptors in cardiac tissue, leading to a reduction in heart rate, cardiac contractility, and systemic blood pressure. The specific entity generic a-University of Florida-hypertension refers to the generic metoprolol extended-release formulation manufactured by Dr. Reddy's Laboratories, which was evaluated in a University of Florida clinical trial (NCT01830309) comparing its pharmacokinetic and pharmacodynamic profiles against the brand-name drug Toprol XL. This study aimed to address concerns regarding the bioequivalence and clinical consistency of generic metoprolol ER products in patients with hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metoprolol succinate extended-release (Dr. Reddy's).